JP2014526883A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526883A5 JP2014526883A5 JP2014517181A JP2014517181A JP2014526883A5 JP 2014526883 A5 JP2014526883 A5 JP 2014526883A5 JP 2014517181 A JP2014517181 A JP 2014517181A JP 2014517181 A JP2014517181 A JP 2014517181A JP 2014526883 A5 JP2014526883 A5 JP 2014526883A5
- Authority
- JP
- Japan
- Prior art keywords
- virus
- seq
- gene
- recombinant
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700605 Viruses Species 0.000 claims description 47
- 210000004027 cell Anatomy 0.000 claims description 32
- 241000712461 unidentified influenza virus Species 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- 230000035772 mutation Effects 0.000 claims description 17
- 229960005486 vaccine Drugs 0.000 claims description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 9
- 241000124008 Mammalia Species 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 241000712431 Influenza A virus Species 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 6
- 210000003501 vero cell Anatomy 0.000 claims description 5
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 230000001902 propagating effect Effects 0.000 claims description 2
- 230000029812 viral genome replication Effects 0.000 claims description 2
- 108090000862 Ion Channels Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 102000004310 Ion Channels Human genes 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 241000713297 Influenza C virus Species 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 241000282465 Canis Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229940124892 FluLaval Drugs 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940117432 influenza b virus antigen Drugs 0.000 description 1
- 229960003971 influenza vaccine Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161501034P | 2011-06-24 | 2011-06-24 | |
| US61/501,034 | 2011-06-24 | ||
| PCT/US2012/043606 WO2012177924A2 (en) | 2011-06-24 | 2012-06-21 | Influenza virus mutants and uses therefor |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017227944A Division JP6496000B2 (ja) | 2011-06-24 | 2017-11-28 | インフルエンザウイルス変異体およびその使用 |
| JP2017227945A Division JP6445662B2 (ja) | 2011-06-24 | 2017-11-28 | インフルエンザウイルス変異体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526883A JP2014526883A (ja) | 2014-10-09 |
| JP2014526883A5 true JP2014526883A5 (cg-RX-API-DMAC10.html) | 2015-08-06 |
| JP6253576B2 JP6253576B2 (ja) | 2017-12-27 |
Family
ID=47423213
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014517181A Expired - Fee Related JP6253576B2 (ja) | 2011-06-24 | 2012-06-21 | インフルエンザウイルス変異体およびその使用 |
| JP2017227945A Expired - Fee Related JP6445662B2 (ja) | 2011-06-24 | 2017-11-28 | インフルエンザウイルス変異体およびその使用 |
| JP2017227944A Active JP6496000B2 (ja) | 2011-06-24 | 2017-11-28 | インフルエンザウイルス変異体およびその使用 |
| JP2019041172A Active JP6870017B2 (ja) | 2011-06-24 | 2019-03-07 | インフルエンザウイルス変異体およびその使用 |
| JP2021068472A Active JP7231666B2 (ja) | 2011-06-24 | 2021-04-14 | インフルエンザウイルス変異体およびその使用 |
| JP2023022678A Pending JP2023071764A (ja) | 2011-06-24 | 2023-02-16 | インフルエンザウイルス変異体およびその使用 |
| JP2025002842A Pending JP2025066111A (ja) | 2011-06-24 | 2025-01-08 | インフルエンザウイルス変異体およびその使用 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017227945A Expired - Fee Related JP6445662B2 (ja) | 2011-06-24 | 2017-11-28 | インフルエンザウイルス変異体およびその使用 |
| JP2017227944A Active JP6496000B2 (ja) | 2011-06-24 | 2017-11-28 | インフルエンザウイルス変異体およびその使用 |
| JP2019041172A Active JP6870017B2 (ja) | 2011-06-24 | 2019-03-07 | インフルエンザウイルス変異体およびその使用 |
| JP2021068472A Active JP7231666B2 (ja) | 2011-06-24 | 2021-04-14 | インフルエンザウイルス変異体およびその使用 |
| JP2023022678A Pending JP2023071764A (ja) | 2011-06-24 | 2023-02-16 | インフルエンザウイルス変異体およびその使用 |
| JP2025002842A Pending JP2025066111A (ja) | 2011-06-24 | 2025-01-08 | インフルエンザウイルス変異体およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (7) | US9284533B2 (cg-RX-API-DMAC10.html) |
| EP (3) | EP4023749A1 (cg-RX-API-DMAC10.html) |
| JP (7) | JP6253576B2 (cg-RX-API-DMAC10.html) |
| KR (7) | KR102080062B1 (cg-RX-API-DMAC10.html) |
| CN (3) | CN106995802B (cg-RX-API-DMAC10.html) |
| AU (5) | AU2012272837B2 (cg-RX-API-DMAC10.html) |
| CA (4) | CA3055006C (cg-RX-API-DMAC10.html) |
| DK (2) | DK3447131T3 (cg-RX-API-DMAC10.html) |
| ES (1) | ES2890427T3 (cg-RX-API-DMAC10.html) |
| MX (4) | MX346625B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2012177924A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3169427B2 (ja) | 1992-04-07 | 2001-05-28 | 新日本製鐵株式会社 | 磁気特性の優れた二方向性珪素鋼板の製造方法 |
| US9474798B2 (en) | 2007-06-18 | 2016-10-25 | Wisconsin Alumni Research Foundation | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
| JP2013507990A (ja) | 2009-10-26 | 2013-03-07 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| EP2590971A4 (en) | 2010-06-17 | 2014-12-10 | Fuzians Biomedicals Inc | COMPOUNDS SUITABLE FOR ANTIVIRAL ACTIVE SUBSTANCES, COMPOSITIONS AND METHOD OF USE THEREOF |
| CN106995802B (zh) | 2011-06-24 | 2021-04-09 | 复尔健有限公司 | 流感病毒突变体及其用途 |
| ES2655051T3 (es) | 2011-08-26 | 2018-02-16 | Wisconsin Alumni Research Foundation | Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas |
| CN104056276B (zh) * | 2013-03-20 | 2017-05-10 | 上海生物制品研究所有限责任公司 | 一种流感病毒减毒活疫苗及其制备方法 |
| JP2016524915A (ja) | 2013-07-15 | 2016-08-22 | ウィスコンシン アルムニ リサーチ ファンデイション | Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス |
| US9757446B2 (en) * | 2014-03-17 | 2017-09-12 | Flugen, Inc. | Influenza virus vectors and uses therefor |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
| WO2017007839A1 (en) | 2015-07-06 | 2017-01-12 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
| JP2019510481A (ja) | 2016-02-19 | 2019-04-18 | ウィスコンシン アルムニ リサーチ ファンデイション | ワクチン開発のための改善されたｂ型インフルエンザウイルス複製 |
| CN110573614B (zh) | 2017-02-27 | 2024-03-29 | 复尔健有限公司 | 针对流感的免疫原性组合物 |
| CN118272323A (zh) * | 2017-02-27 | 2024-07-02 | 复尔健有限公司 | 流感b病毒突变体及其用途 |
| CN107151659B (zh) * | 2017-03-01 | 2021-04-02 | 苏州系统医学研究所 | 一种流感病毒株及其应用 |
| WO2019084310A1 (en) | 2017-10-25 | 2019-05-02 | Yoshihiro Kawaoka | HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION |
| US12343390B2 (en) | 2018-08-07 | 2025-07-01 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| US11389523B2 (en) | 2018-08-20 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein |
| EP3914295A2 (en) | 2019-01-23 | 2021-12-01 | Yoshihiro Kawaoka | Mutations that confer genetic stability to additional genes in influenza viruses |
| WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
| KR102370100B1 (ko) | 2019-02-15 | 2022-03-07 | 아이디바이오 주식회사 | 이종 인플루엔자 a 바이러스에 대한 면역/치료반응을 형성하는 신규한 재조합 인플루엔자 바이러스 및 이를 포함하는 유전자 전달체 및 치료백신 |
| US11214799B2 (en) | 2019-03-12 | 2022-01-04 | The University Court Of The University Of Edinburg Old College | HA-specific influenza virus attenuated vaccine comprising mutations in segment 7, and uses therefor |
| CN114929269A (zh) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | 用于疫苗开发的改进的流感病毒复制 |
| EP3980060A4 (en) | 2019-06-07 | 2023-04-12 | Flugen, Inc. | FLU VIRUS BACKBONE |
| CN110468130B (zh) * | 2019-08-09 | 2021-08-06 | 中国人民解放军军事科学院军事医学研究院 | 流感长链非编码RNA-lnc330及其应用 |
| WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
| JP2023511444A (ja) | 2020-01-24 | 2023-03-17 | ウィスコンシン アルムニ リサーチ ファンデイション | 安定化されたｎａを有する組換えインフルエンザウイルス |
| WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| WO2022020469A1 (en) | 2020-07-21 | 2022-01-27 | Flugen, Inc. | Influenza virus backbone |
| CN114381438B (zh) * | 2022-01-27 | 2024-02-02 | 浙江迪福润丝生物科技有限公司 | 一种流感病毒的致弱方法及流感致弱病毒株和应用 |
| CN114410681B (zh) * | 2022-01-27 | 2024-02-13 | 浙江迪福润丝生物科技有限公司 | 一种基于m基因核苷酸片段删除的流感病毒的致弱方法以及致弱流感病毒株和应用 |
| CN114438043B (zh) * | 2022-01-27 | 2023-12-15 | 浙江迪福润丝生物科技有限公司 | 一种区分感染和免疫的致弱流感病毒疫苗株及疫苗 |
| CN114381439B (zh) * | 2022-01-27 | 2023-12-15 | 浙江迪福润丝生物科技有限公司 | 一种同义突变结合删除突变的流感病毒的致弱方法及致弱流感病毒株和应用 |
| CN114381440B (zh) * | 2022-01-27 | 2023-12-15 | 浙江迪福润丝生物科技有限公司 | 一组基于同义突变和/或缺失突变的a型流感病毒致弱毒株及其制备方法和应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6253576U (cg-RX-API-DMAC10.html) | 1985-09-21 | 1987-04-02 | ||
| JPH05515Y2 (cg-RX-API-DMAC10.html) | 1987-12-16 | 1993-01-08 | ||
| CA2275605A1 (en) * | 1996-12-20 | 1998-07-02 | The Procter & Gamble Company | A dry laid structure comprising particulate material |
| GB9815040D0 (en) * | 1998-07-10 | 1998-09-09 | Medical Res Council | Conditional mutant |
| AU5533601A (en) * | 2000-04-14 | 2001-10-30 | Wisconsin Alumni Res Found | Viruses comprising mutation ion channel protein |
| EP1364006A2 (en) | 2001-02-23 | 2003-11-26 | Wisconsin Alumni Research Foundation | Methods to identify mutant cells with altered sialic acid |
| JP2007525175A (ja) * | 2003-04-23 | 2007-09-06 | ウィスコンシン アルムニ リサーチ ファウンデイション | 突然変異した膜タンパク質をその機能性の一部ウイルス |
| ES2593082T3 (es) * | 2003-05-28 | 2016-12-05 | Wisconsin Alumni Research Foundation | Virus de la gripe recombinantes a título elevado para vacunas y terapia génica |
| CA2536249A1 (en) * | 2003-08-25 | 2005-03-10 | 3M Innovative Properties Company | Delivery of immune response modifier compounds |
| CN1810961B (zh) * | 2006-02-22 | 2010-05-12 | 中国人民解放军军事医学科学院微生物流行病研究所 | 一种重组流感病毒及其制备方法与应用 |
| US9474798B2 (en) * | 2007-06-18 | 2016-10-25 | Wisconsin Alumni Research Foundation | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
| AU2008321016B2 (en) * | 2007-11-12 | 2013-03-28 | Theraclone Sciences, Inc. | Compositions and methods for the therapy and diagnosis of influenza |
| EP2296701A1 (en) | 2008-06-11 | 2011-03-23 | Flugen, Inc. | Cell-based systems for producing influenza vaccines |
| US20100061995A1 (en) * | 2008-09-08 | 2010-03-11 | Damian Michael Carragher | Immunotherapy To Treat Or Prevent Viral Infection |
| KR20120018783A (ko) * | 2009-05-01 | 2012-03-05 | 레드바이오텍 아게 | 다중 유전자 벡터에 의해 암호화된 재조합 바이러스-유사 입자 |
| US20110172637A1 (en) | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Drug delivery device including tissue support structure |
| US20110172639A1 (en) | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Device and method for delivery of microneedle to desired depth within the skin |
| US20110172609A1 (en) | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Microneedle component assembly for drug delivery device |
| US20110172638A1 (en) | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Drug delivery device including multi-functional cover |
| US20110172645A1 (en) | 2010-01-08 | 2011-07-14 | Ratio, Inc. | Wearable drug delivery device including integrated pumping and activation elements |
| US8668675B2 (en) | 2010-11-03 | 2014-03-11 | Flugen, Inc. | Wearable drug delivery device having spring drive and sliding actuation mechanism |
| TW201303143A (zh) | 2011-03-22 | 2013-01-16 | Exxonmobil Upstream Res Co | 低排放渦輪機系統中用於攫取二氧化碳及產生動力的系統與方法 |
| CN106995802B (zh) | 2011-06-24 | 2021-04-09 | 复尔健有限公司 | 流感病毒突变体及其用途 |
| JP6639334B2 (ja) | 2016-06-20 | 2020-02-05 | 株式会社日立製作所 | 業務処理フロー生成システム、生成方法および装置 |
| JP6120237B1 (ja) | 2016-06-20 | 2017-04-26 | 仁博 平嶋 | サービスシステム、アプリケーションプログラム及び決済方法 |
-
2012
- 2012-06-21 CN CN201611019615.4A patent/CN106995802B/zh not_active Expired - Fee Related
- 2012-06-21 KR KR1020187023462A patent/KR102080062B1/ko not_active Expired - Fee Related
- 2012-06-21 CA CA3055006A patent/CA3055006C/en active Active
- 2012-06-21 EP EP21186144.8A patent/EP4023749A1/en active Pending
- 2012-06-21 CN CN201280040857.5A patent/CN103781901B/zh active Active
- 2012-06-21 EP EP12803054.1A patent/EP2723855B1/en active Active
- 2012-06-21 WO PCT/US2012/043606 patent/WO2012177924A2/en not_active Ceased
- 2012-06-21 EP EP18183256.9A patent/EP3447131B1/en active Active
- 2012-06-21 ES ES18183256T patent/ES2890427T3/es active Active
- 2012-06-21 CN CN201811230716.5A patent/CN109652430B/zh active Active
- 2012-06-21 KR KR1020147001965A patent/KR102080914B1/ko active Active
- 2012-06-21 KR KR1020187023457A patent/KR102080061B1/ko not_active Expired - Fee Related
- 2012-06-21 KR KR1020217020817A patent/KR102446975B1/ko active Active
- 2012-06-21 DK DK18183256.9T patent/DK3447131T3/da active
- 2012-06-21 KR KR1020227032675A patent/KR102628482B1/ko active Active
- 2012-06-21 CA CA3103774A patent/CA3103774A1/en not_active Abandoned
- 2012-06-21 CA CA2875484A patent/CA2875484C/en active Active
- 2012-06-21 JP JP2014517181A patent/JP6253576B2/ja not_active Expired - Fee Related
- 2012-06-21 AU AU2012272837A patent/AU2012272837B2/en active Active
- 2012-06-21 MX MX2014000254A patent/MX346625B/es active IP Right Grant
- 2012-06-21 KR KR1020207004751A patent/KR102275459B1/ko active Active
- 2012-06-21 MX MX2017003937A patent/MX383065B/es unknown
- 2012-06-21 US US14/128,415 patent/US9284533B2/en active Active
- 2012-06-21 MX MX2017003936A patent/MX361139B/es unknown
- 2012-06-21 CA CA3055002A patent/CA3055002C/en active Active
- 2012-06-21 KR KR1020247002143A patent/KR20240013286A/ko not_active Ceased
- 2012-06-21 DK DK12803054.1T patent/DK2723855T3/en active
-
2014
- 2014-01-07 MX MX2021006342A patent/MX2021006342A/es unknown
-
2016
- 2016-02-10 US US15/040,277 patent/US9919042B2/en not_active Expired - Fee Related
- 2016-02-10 US US15/040,705 patent/US9919043B2/en not_active Expired - Fee Related
-
2017
- 2017-11-28 JP JP2017227945A patent/JP6445662B2/ja not_active Expired - Fee Related
- 2017-11-28 JP JP2017227944A patent/JP6496000B2/ja active Active
-
2018
- 2018-01-22 AU AU2018200490A patent/AU2018200490B2/en not_active Ceased
- 2018-01-22 AU AU2018200488A patent/AU2018200488B2/en not_active Ceased
- 2018-03-12 US US15/917,926 patent/US11040098B2/en active Active
-
2019
- 2019-03-07 JP JP2019041172A patent/JP6870017B2/ja active Active
- 2019-03-28 US US16/368,315 patent/US11207399B2/en active Active
-
2020
- 2020-03-10 AU AU2020201760A patent/AU2020201760B2/en active Active
-
2021
- 2021-04-14 JP JP2021068472A patent/JP7231666B2/ja active Active
- 2021-12-22 US US17/558,852 patent/US11980661B2/en active Active
-
2023
- 2023-02-16 JP JP2023022678A patent/JP2023071764A/ja active Pending
- 2023-06-29 AU AU2023204165A patent/AU2023204165A1/en not_active Abandoned
-
2024
- 2024-04-08 US US18/629,503 patent/US20250090649A1/en active Pending
-
2025
- 2025-01-08 JP JP2025002842A patent/JP2025066111A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Advances in development and application of influenza vaccines | |
| Auladell et al. | Recalling the future: immunological memory toward unpredictable influenza viruses | |
| Wong et al. | Traditional and new influenza vaccines | |
| Chroboczek et al. | Virus-like particles as vaccine. | |
| Metz et al. | Effective chikungunya virus-like particle vaccine produced in insect cells | |
| CN109477074B (zh) | 用于疫苗开发的改进的乙型流感病毒复制 | |
| Park et al. | Immunogenicity and protective efficacy of an intranasal live-attenuated vaccine against SARS-CoV-2 | |
| EP2493912B1 (en) | High titer recombinant influenza viruses with enhanced replication in vero cells | |
| JP7627911B2 (ja) | 卵内複製のための安定化されたｈａを持つ組換えインフルエンザウイルス | |
| Ahata et al. | CCHFV vaccine development, current challenges, limitations, and future directions | |
| WO2021150874A1 (en) | Recombinant influenza viruses with stabilized na | |
| JP2021536228A (ja) | ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター | |
| US20230310583A1 (en) | Recombinant newcastle disease virus expressing sars-cov-2 spike protein and uses thereof | |
| Márquez-Escobar | Current developments and prospects on human metapneumovirus vaccines | |
| Petro-Turnquist et al. | Swine influenza A virus: challenges and novel vaccine strategies | |
| Lee et al. | AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection | |
| Yu et al. | Recent research advances in the development of Dabie Banda virus vaccines | |
| Luo et al. | Virus-like particles containing a prefusion-stabilized F protein induce a balanced immune response and confer protection against respiratory syncytial virus infection in mice | |
| McMurry et al. | A call to cellular & humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A | |
| Yang et al. | Progress in African swine fever vector vaccine development | |
| Zhao et al. | Adjuvant-free, self− assembling ferritin nanoparticle vaccine coupled with influenza virus hemagglutinin protein carrying M1 and PADRE epitopes elicits cross-protective immune responses | |
| Sircy et al. | Generation of antigen-specific memory CD4 T cells by heterologous immunization enhances the magnitude of the germinal center response upon influenza infection | |
| Di et al. | The self-assembled nanoparticle-based multi-epitope influenza mRNA vaccine elicits protective immunity against H1N1 and B influenza viruses in mice | |
| Yuan et al. | Advancements in the application and research of baculovirus vector vaccines for respiratory diseases in human | |
| Zhang et al. | Rational design of self-amplifying virus-like vesicles with Ebola virus glycoprotein as vaccines |